Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines

William E Boden1, Raffaele De Caterina2, Juan Carlos Kaski3

  • 1VA Boston Healthcare System, Boston University School of Medicine, 150 S. Huntington Avenue, Boston, MA 02130, USA.

European Heart Journal
|August 30, 2024
PubMed

Insights

New classifications for myocardial ischaemia aim to unify terminology, encompassing both obstructive and non-obstructive causes. This aims to improve diagnosis and treatment for conditions like chronic coronary syndromes and acute myocardial infarction.

Area of Science:

  • Cardiology
  • Medical Terminology
  • Ischaemic Heart Disease

Background:

  • Current classifications for chronic myocardial ischaemia use conflicting terms like 'stable coronary artery disease' (CAD) and 'chronic coronary syndromes' (CCS).
  • Competing guidelines (European vs. American) have introduced divergent terminology, causing confusion.
  • Existing terms like 'coronary' and 'disease' often narrowly focus on obstructive CAD, excluding other mechanisms.

Purpose of the Study:

  • To propose a new, inclusive binary classification for myocardial ischaemia.
  • To unify disparate nomenclatures across international guidelines.
  • To foster conceptual clarity for both obstructive and non-obstructive causes of angina and myocardial ischaemia.

Main Methods:

  • Proposed a binary classification: 'acute myocardial ischaemic syndromes' and 'non-acute myocardial ischaemic syndromes'.
  • Included both obstructive epicardial and non-obstructive pathogenetic mechanisms (e.g., microvascular dysfunction, vasospastic disorders).
  • Retained established categories of acute coronary syndromes (ACS) and myocardial infarction (MI) subtypes.

Main Results:

  • The proposed classification encompasses a broader range of pathogenetic mechanisms.
  • It includes conditions like ischaemia and MI with non-obstructive coronary arteries.
  • The new nomenclature harmonizes different pathophysiologic causes of myocardial ischaemia.

Conclusions:

  • The proposed classification offers a more encompassing nomenclature for myocardial ischaemia.
  • It better aligns and unifies diagnostic and therapeutic approaches.
  • This should lead to more refined treatments targeting diverse pathobiological precipitants of angina, ischaemia, and infarction.

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
547
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404